### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Tech Mpire Limited

ABN

88 156 377 141

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>†</sup>Class of \*securities issued or to be issued

Fully paid ordinary shares

Number of \*securities issued or to be issued (if known) or maximum number which may be issued 7,500,000

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares for which quotation will be sought

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Issued at nil cost on conversion of Class B Performance Rights which have vested
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued on vesting of Class B Performance Rights
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	24 October 2016
6c	Number of *securities issued without security holder approval under rule 7.1	nil
6d	Number of *securities issued with security holder approval	nil

under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued	nil
	with security holder approval	
	under rule 7.3, or another	
	specific security holder approval	
	(specify date of meeting)	

6f Number of \*securities issued under an exception in rule 7.2

7,500,000

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Rule 7.1 10,996,150 Rule 7.1A 7,330,767

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

31 August 2017

8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number	<sup>+</sup> Class
73,307,669	Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9	Number and	+class	of	all
	+securities not q	uoted	on A	SX
	(including the	+secur	ities	in
	section 2 if applic	able)		

Number	+Class
7,000,000	Options (\$0.50, 29 June 2018).
1,500,000	Options (\$0.45, 30 March 2020)
33,332	Class D Performance Rights, Conversion ratio into ordinary shares is 1:1.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

#### Part 2 - Pro rata issue

- Is security holder approval required?
- Is the issue renounceable or non-renounceable?
- Ratio in which the \*securities will be offered N/A
- <sup>+</sup>Class of <sup>+</sup>securities to which the offer relates N/A
- 15 \*Record date to determine N/A entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- Policy for deciding entitlements in relation to fractions

<sup>+</sup> See chapter 19 for defined terms.

10	entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through	N/A

<sup>+</sup> See chapter 19 for defined terms.

	a broker?			
31	How do security holders sell <i>para</i> of their entitlements through a broker and accept for the balance?			
32	How do security holders dispose of their entitlements (except by sale through a broker)?			
33	<sup>+</sup> Issue date	N/A		
	<b>3 - Quotation of securiti</b> <i>ed only complete this section if you are</i> Type of *securities ( <i>tick one</i> )			
(a)	*Securities described in Pa	rt ı		
(b)		end of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of convertible		
Entities that have ticked box 34(a)				
Addı	tional securities forming a ne	ew class of securities		
Tick to docum	indicate you are providing the informents	ation or		
35		ty securities, the names of the 20 largest holders of the the number and percentage of additional <sup>+</sup> securities		
36		ty securities, a distribution schedule of the additional number of holders in the categories		

<sup>+</sup> See chapter 19 for defined terms.

		_		
	Entiti	ies that have ticked box 34(b)		
	38	Number of *securities for which *quotation is sought		
	39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
15	40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
<u> </u>		If the additional *securities do not rank equally, please state:  (b) the date from which they do		
		(c) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment (d) the extent to which they		
		do not rank equally, other than in relation to the next dividend, distribution or interest payment		
	41	Reason for request for quotation now		
15		Example: In the case of restricted securities, end of restriction period		
		(if issued upon conversion of another *security, clearly identify that other *security)		
			Number	+Class
	42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	Class

A copy of any trust deed for the additional  ${}^{+}$ securities

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 31 August 2017

(Director/Company secretary)

Print name: Clare Madelin

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	65,774,335		
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	7/6/17 – 33,334 on conversion of Class C performance rights 31/8/17 – 7,500,000 on conversion of Class B performance rights  nil		
"A"	73,307,669		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	10,996,150
Step 3: Calculate "C", the amount of the control of	of placement capacity under rule
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
<ul> <li>Under an exception in rule 7.2</li> </ul>	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	nil
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	10,996,150
Note: number must be same as shown in Step 2	
Subtract "C"	nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	10,996,150
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
		"A"
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	7,330,767	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	nil	
"E"	nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	7,330,767	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	7,330,767	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.